Moleculin Biotech, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.3M
- Price
- $0.5935
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.49%
- Volume
- 280.2K
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Quick stats
Shares outstanding19.5M
Computed float4.9M
Float / shares25.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001659617
Websitehttps://www.moleculin.com
AI Summary
AI-generated1/23
majorbullishearnings
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Moleculin reported a Q2 net loss of $7.6 million, or $(1.40) per share, with cash and equivalents of $7.3 million as of June 30.
The company raised $9.3 million in financing after the quarter-end, extending its expected cash runway into the first quarter of 2027 to support ongoing operations.
Interim data from the pivotal MIRACLE trial showed Annamycin achieved complete remission rates of 43% and 36%, versus 12% for the control arm, with enrollment on track to reach 90 patients by September 2026.
Red flags
- Cash runway only extends into Q1 2027, requiring further financing
- Pre-revenue status with increasing R&D expenses